| P50 | author | Alan F List | Q63634762 |
| | Frederick R. Appelbaum | Q75025725 |
| | Thomas R Chauncey | Q75025754 |
| | Harry P Erba | Q93114769 |
| | Cheryl L. Willman | Q110811050 |
| | Marilyn L Slovak | Q114428079 |
| | Holly Gundacker | Q114777553 |
| | Shaker R Dakhil | Q114777556 |
| P2093 | author name string | Mazyar Shadman | |
| | I-Ming Chen | |
| | Kenneth J Kopecky | |
| P2860 | cites work | Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study | Q28139696 |
| | Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML) | Q28216376 |
| | Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. | Q30444746 |
| | Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial | Q33264716 |
| | A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). | Q33502338 |
| | Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) | Q33758413 |
| | Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study | Q34528336 |
| | Age and acute myeloid leukemia | Q34564663 |
| | Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies | Q35817464 |
| | Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction | Q35848938 |
| | Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. | Q35849784 |
| | CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. | Q35880840 |
| | Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia | Q37919763 |
| | Cyclosporin A is a broad-spectrum multidrug resistance modulator | Q40443016 |
| | Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | Q40543180 |
| | Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. | Q41175330 |
| | Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL. | Q41483617 |
| | Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). | Q41692610 |
| | A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617. | Q43417536 |
| | MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia | Q43615393 |
| | Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial | Q43622754 |
| | Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial | Q43718516 |
| | Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study | Q43806484 |
| | Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. | Q44083625 |
| | Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. | Q44102028 |
| | Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia | Q44381147 |
| | Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources | Q44578925 |
| | Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr | Q45130073 |
| | A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. | Q46183389 |
| | The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis | Q46580597 |
| | Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study. | Q54104948 |
| | Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. | Q54233564 |
| | Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk | Q73181830 |
| | Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study | Q73292530 |
| | Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study | Q78039803 |
| | Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma | Q79765272 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| | cytarabine | Q180983 |
| | cyclosporine | Q367700 |
| | daunorubicin | Q411659 |
| P304 | page(s) | 48-58 | |
| P577 | publication date | 2009-10-11 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia | |
| P478 | volume | 148 | |